The main products in Stallergenes’s injectable and sublingual ranges will soon be the subject of registration applications. This partnership reportedly enables Stallergenes to meet more than 80% of the needs of allergy sufferers in Russia and the Commonwealth of Independent States by 2011.
Albert Saporta, chairman and CEO of Stallergenes, said: “We’re delighted to be teaming up with Solvay Pharmaceuticals to target the potential growth this new market represents. Thanks to its franchise and its considerable expertise recognized by allergy specialists, Solvay Pharmaceuticals will enable us to promote the desensitization standardized products, and notably the sublingual route, and their benefits for patients.”